Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: Current understanding, challenges and recommendations

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 241-253

  Teo, Yi Ling ^a   Ho, Han Kiat ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

cytochrome P450; drug metabolism; drug drug interactions; pharmacokinetics; tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; AXITINIB; BOSUTINIB; CABOZANTINIB; CAPECITABINE; CRIZOTINIB; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; KETOCONAZOLE; LAPATINIB; NAVELBINE; NILOTINIB; PAZOPANIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; RIFAMPICIN; SIMVASTATIN; SORAFENIB; SUNITINIB; VANDETANIB; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; ENZYME INHIBITION; HORMONE SUBSTITUTION; HUMAN; LIVER FUNCTION; LUNG CANCER; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TOXIC HEPATITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84941132562     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12496     Document Type: Article

References (87)

1. Tyler T,. Drug interactions in metastatic breast cancer. J Oncol Pharm Pract 2011; 17: 236-245.
2. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ,. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 2013; 88: 139-148.
3. Hadjibabaie M, Badri S, Ataei S, Moslehi AH, Karimzadeh I, Ghavamzadeh A,. Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol 2013; 71: 1619-1627.
4. Ko Y, Tan SLD, Chan A, Wong YP, Yong WP, Ng RCH, Lim SW, Salim A,. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther 2012; 34: 1696-1704.
5. Chan A, Tan SH, Wong CM, Yap KYL, Ko Y,. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a delphi survey of oncology pharmacists. Clin Ther 2009; 31: 2379-2386.
6. Lees J, Chan A,. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 2011; 12: 1249-1257.
7. Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S,. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. J Clin Pharm Ther 2014; 39: 259-265.
8. Fujita KI,. Cytochrome P450 and anticancer drugs. Curr Drug Metab 2006; 7: 23-37.
9. Teo YL, Saetaew M, Chanthawong S, Yap YS, Yong Chan EC, Ho HK, Chan A,. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 2012; 133: 703-711.
10. Rosenbaum S, Wu S, Newman M, West D, Kuzel T, Lacouture M,. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16: 557-566.
11. Teo YL, Chong XJ, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A,. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemother Pharmacol 2013; 73: 381-388.
12. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, Seiberling M,. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004; 54: 290-294.
13. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D,. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 2011; 51: 1721-1727.
14. Scripture CD, Figg WD,. Drug interactions in cancer therapy. Nat Rev Cancer 2006; 6: 546-558.
15. Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T,. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D 2011; 11: 37-51.
16. Bosulif (bosutinib) prescribing information. Pfizer; 2013.
17. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ,. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011; 68: 1111-1118.
18. Takimoto CH, Awada A,. Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008; 61: 535-548.
19. Infante JR, Jones SF, Bendell JC, Greco FA, Yardley DA, Lane CM, Spigel DR, Hainsworth JD, Burris Iii HA,. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer Chemother Pharmacol 2012; 69: 137-144.
20. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R, Fischer T,. Effects of imatinib mesylate (ST1571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003; 89: 1855-1859.
21. Wang Y, Zhou L, Dutreix C, Leroy E, Yin Q, Sethuraman V, Riviere GJ, Yin OQP, Schran H, Shen ZX,. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008; 65: 885-892.
22. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ,. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005; 44: 1067-1081.
23. Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA,. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 2013; 15: 490-496.
24. De Jonge MJA, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI,. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 2013; 31: 751-759.
25. Brain E, Isambert N, Dalenc F, Diéras V, Bonneterre J, Rezai K, Jimenez M, Mefti-Lacheraf F, Cottura E, Tresca P, Vanlemmens L, Mahier-Aït Oukhatar C, Lokiec F, Fumoleau P,. Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer 2012; 106: 673-677.
26. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A,. The Simcyp® population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223.
27. Shapiro LE, Shear NH,. Drug interactions: proteins, pumps, and P-450s. J Am Acad Dermatol 2002; 47: 467-484.
28. Pal D, Mitra AK,. CYP3A4 and MDR mediated interactions in drug therapy. Clin Res Regul Aff 2006; 23: 125-163.
29. Purnapatre K, Khattar SK, Saini KS,. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 2008; 259: 1-15.
30. Pajares B, Torres E, Trigo JM, Sáez MI, Ribelles N, Jiménez B, Alba E,. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol 2012; 14: 94-101.
31. Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, Khojasteh SC,. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 2012; 29: 1960-1976.
32. Castellino S, O'Mara M, Koch K, Borts DJ, Bowers GD, MacLauchlin C,. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 2012; 40: 139-150.
33. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N,. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-2009.
34. Uetrecht J,. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513-539.
35. Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W,. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos 2014; 42: 744-750.
36. Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, Kovacsovics T, Panizzon RG,. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 2005; 211: 363-365.
37. Xu CF, Xue Z, Bing N, King KS, McCann LA, De PL, Goodman VL, Spraggs CF, Mooser VE, Pandite LN,. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol 2012; 23: 2470-2471.
38. Seminerio MJ, Ratain MJ,. Are drug labels static or dynamic? Clin Pharmacol Ther 2013; 94: 302-304.
39. Seminerio MJ, Ratain MJ,. Preventing adverse drug-drug interactions: a need for improved data and logistics. Mayo Clin Proc 2013; 88: 126-128.
40. Wu K, House L, Ramírez J, Seminerio MJ, Ratain MJ,. Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. Clin Cancer Res 2013; 19: 6039-6043.
41. Duckett DR, Cameron MD,. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 2010; 6: 1175-1193.
42. Hanigan MH, Dela Cruz BL, Shord SS, Medina PJ, Fazili J, Thompson DM,. Optimizing chemotherapy: concomitant medication lists. Clin Pharmacol Ther 2011; 89: 114-119.
43. Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferraù F,. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010; 36: 595-605.
44. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK,. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600.
45. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, Krzyzanowska MK,. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008; 35: 535-543.
46. Blower P, De Wit R, Goodin S, Aapro M,. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005; 55: 117-142.
47. Szałek E, Karbownik A, Połom W, Matuszewski M, Sobańska K, Urjasz H, Grabowski T, Wolc A, Grzes̈kowiak E,. Sunitinib in combination with clarithromycin or azithromycin-Is there a risk of interaction or not? Pharmacol Rep 2012; 64: 1554-1559.
48. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H,. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 2012; 30: 4017-4025.
49. Josephs DH, Fisher DS, Spicer J, Flanagan RJ,. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit 2013; 35: 562-587.
50. Yu H, Steeghs N, Nijenhuis CM, Schellens JHM, Beijnen JH, Huitema ADR,. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 2014; 53: 305-325.
51. Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A,. Review of therapeutic drug monitoring of anticancer drugs part two-targeted therapies. Eur J Cancer 2014; 50: 2020-2036.
52. Gilotrif (afatinib) prescribing information. Boehringer Ingelheim; 2013.
53. Inlyta (axitinib) prescribing information. Pfizer; 2013.
54. Cometriq (cabozantinib) prescribing information. Exelixis; 2012.
55. Xalkori (crizotinib) prescribing information. Pfizer; 2014.
56. Sprycel (dasatinib) prescribing information. Bristol-Myers Squibb; 2014.
57. Tarceva (erlotinib) prescribing information. OSI Pharmaceuticals; 2014.
58. Iressa (gefitinib) prescribing information. AstraZeneca; 2005.
59. Gleevec (imatinib) prescribing information. Novartis; 2014.
60. Tykerb (lapatinib) prescribing information. GlaxoSmithKline; 2013.
61. Tasigna (nilotinib) prescribing information. Novartis; 2014.
62. Votrient (pazopanib) prescribing information. GlaxoSmithKline; 2014.
63. Iclusig (ponatinib) prescribing information. Ariad Pharmaceuticals; 2014.
64. Stivarga (regorafenib) prescribing information. Bayer; 2013.
65. Nexavar (sorafenib) prescribing information. Bayer; 2013.
66. Sutent (sunitinib) prescribing information. Pfizer; 2013.
67. Caprelsa (vandetanib) prescribing information. AstraZeneca; 2014.
68. Food and Drug Administration. Product label information. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (last accessed July 2014).
69. European Medicines Agency. European public assessment reports. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines-landing-page.jspandmid= (last accessed August 2014).
70. Pithavala YK, Tong W, Mount J, Rahavendran SV, Garrett M, Hee B, Selaru P, Sarapa N, Klamerus KJ,. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 2012; 30: 273-281.
71. Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ,. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010; 65: 563-570.
72. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA,. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010; 116: 1582-1591.
73. 14C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol 2009; 68: 226-237.
74. Filppula AM, Tornio A, Niemi M, Neuvonen PJ, Backman JT,. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin Pharmacol Ther 2013; 94: 383-393.
75. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M,. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004; 53: 102-106.
76. Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser M, Dresemann G,. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 2008; 3: 198-203.
77. Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A,. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009; 67: 421-426.
78. Tanaka C, Yin OQP, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H,. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011; 51: 75-83.
79. Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, Gregory C, Suttle AB, Tada H, Botbyl J, Stephenson JJ,. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 2013; 71: 1635-1643.
80. Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D,. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol 2013; 53: 974-981.
81. Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF,. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer 2014; 120: 1194-1202.
82. Carlini P, Papaldo P, Fabi A, Felici A, Ruggeri EM, Milella M, Ciccarese M, Nuzzo C, Cognetti F, Ferretti G,. Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol 2006; 24: e60-61.
83. Arai S, Mitsufuji H, Nishii Y, Onoda S, Ryuge S, Wada M, Katono K, Iwasaki M, Takakura A, Otani S, Yamamoto M, Yanaihara T, Yokoba M, Kubota M, Katagiri M, Fukui T, Kobayashi H, Yanase N, Hataishi R, Masuda N,. Effect of gefitinib on warfarin antithrombotic activity. Int J Clin Oncol 2009; 14: 332-336.
84. Ross DM,. Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine. Intern Med J 2009; 39: 708.
85. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U,. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 2011; 50: 551-603.
86. de Groot JWB, Links TP, van der Graaf WTA,. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 2006; 17: 1719-1720.
87. Noda S, Shioya M, Hira D, Fujiyama Y, Morita SY, Terada T,. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer Chemother Pharmacol 2013; 72: 269-272.